Immunotolerx Inc.

Immunotolerx Inc. is advancing a novel nanoparticle-based immunotherapy platform that harnesses the body’s natural tolerance pathway. By mimicking apoptotic cell signals through phosphatidylserine (PS)-containing liposomes, our approach induces regulatory immune responses to “re-educate” the immune system. Our goal is to halt or reverse autoimmune disease progression and prevent unwanted immune reactions, including anti-drug antibodies to biologics and gene therapy vectors.